个人简介

毕业于第二军医大学（肿瘤学硕士），目前浙江大学肿瘤学博士在读，至今以第一/共同第一作者发表SCI论文10余篇。

专业擅长

擅长肺癌、乳腺癌、胃癌肠癌等消化道肿瘤、泌尿系和妇科肿瘤等各类癌症的化疗、靶向治疗和免疫治疗，倡导肿瘤患者全程管理和精准治疗。

研究方向

 消化道肿瘤和肺癌发病机制和临床转化性研究。

成果奖项：（近五年主要成果及奖励情况）

(1) Qi Jiang^#, Mixue Xie^#, Ruyin Chen^#, Feifei Yan, Chanqi Ye, Qiong Li, Shuaishuai Xu, Wei Wu, Yunlu Jia^*, Peng Shen^* Jian Ruan^*; Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments, Frontiers in Immunology, 2022, 13: 973601

(2) Feifei Yan^#, Qi Jiang^#, Bin Ru, Xiaojie Fei, Jian Ruan, Xiaochen Zhang^*; Metastatic urothelial carcinoma harboring ERBB2/3 mutations dramatically respond to chemotherapy plus anti-PD-1 antibody: A case report, World Journal of Clinical Cases, 2022, 10(8): 2497-2503

(3) Luo Wang^#, Qi Jiang^#, MengYe He, Peng Shen^*; HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review, World Journal of Clinical Cases, 2022, 10(1): 260-267

(4) Feifei Yan^#, Qi Jiang^#, Mengye He^*, Peng Shen^*;PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis, Future Oncology. 2021,17(18):2381-2393.

(5) Mixue Xie^#; Qi Jiang^#; Shuqi Zhao; Jing Zhao; Xiujin Ye^*; Wenbin Qian^*; Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis, International Immunopharmacology, 2020, 85:106684.

(6) Qi Jiang^#; Mixue Xie^#; Xiaochen Zhang^*; Complete response to trastuzumab and chemotherapy in recurrent urothelial bladder carcinoma with HER2 gene amplification: A case report, World Journal of Clinical Cases, 2020, v.8(03):112-117.

(7) Qi Jiang^#; Mixue Xie^#; Mengye He; Feifei Yan; Ming Chen; Suzhen Xu; Xiaochen Zhang^*; Peng Shen^*; PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer, Medicine, 2019, 98:1(e13820).

(8) Qi Jiang^#; Peng Shen^*; Assessment quality of life with hand-foot syndrome induced by apatinib combined with anti-PD-1 therapy in NSCLC, Annals of Oncology, 2019,30(sup 5).

(9) Yao Chen^#, Xiaochen Zhang, Qi Jiang, BoWang, Yina Wang^*, JunrongYan; Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib, Lung Cancer, 2020, 146:370-372.

(10) Mixue Xie^#, Lulu Wang^#, Qi Jiang, Xuxia Luo, Xin Zhao, Xueying Li, Jie Jin, Xiujin Ye^*, Kui Zhao^*;Signifcance of initial, interim and end-of-therapy 18F-FDG PET/CT for predicting transformation risk in follicular lymphoma, Cancer Cell International, 2021, 21:394.

(11) Wen Lei^#, Mixue Xie^#, Qi Jiang, Nengwen Xu, Ping Li, Aibin Liang, Ken H. Young, Wenbin Qian^*; Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis, Cancers, 2021, 13, 3912.

(12) Suzhen Xu^#, Xiaochen Zhang^#, Qi Jiang, Ming Chen, Mengye He, Peng Shen^*; Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report, World Journal of Clinical Cases, 2022, 10(28): 10236-10243

(13) Ruyin Chen^#, Dandan Zheng^#, Qiong Li^#, Shuaishuai Xu, Chanqi Ye, Qi Jiang, Feifei Yan, Yunlu Jia^*, Xiaochen Zhang^*, Jian Ruan^*; Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers, Cancer Letters, 2022, 546: 215853

(14) Qiong Li^#, Chanqi Ye^#, Tian Tian, Qi Jiang, Peng Zhao, Xiaoting Wang, Feiye Liu, Jianzhen Shan, Jian Ruan^*; The emerging role of ubiquitin-specific protease 20 in tumorigenesis and cancer therapeutics, Cell Death and Disease, 2022, 13(5): 434

(15) Ruyin Chen^#, Qiong Li^#, Shuaishuai Xu^#, Chanqi Ye, Tian Tian, Qi Jiang, Jianzhen Shan^*, Jian Ruan^*; Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment, Cancer Cell International, 2022, 22(1): 73

(16) Kaili Cen^#, Ming Chen^#, Mengye He^#, Zhenhao Li, Yinjing Song, Pu Liu, Qi Jiang, Suzhen Xu, Yunlu Jia^*, Peng Shen^*; Sporoderm-Broken Spores of Ganoderma lucidum Sensitizes Ovarian Cancer to Cisplatin by ROS/ERK Signaling and Attenuates Chemotherapy-Related Toxicity, Frontiers in Pharmacology, 2022, 13: 826716

(17) Jian Ruan^#, Shuaishuai Xu^#, Ruyin Chen^#, Wenxin Qu, Qiong Li, Chanqi Ye, Wei Wu, Qi Jiang, Feifei Yan, Enhui Shen, Qinjie Chu, Yunlu Jia, Xiaochen Zhang, Wenguang Fu, Jinzhang Chen, Michael P Timko, Peng Zhao^*, Longjiang Fan^*, Yifei Shen^*; EMLI-ICC: an ensemble machine learning-based integration algorithm for metastasis prediction and risk stratification in intrahepatic cholangiocarcinoma, Briefings in Bioinformatics, 2022, 18: bbac450

（18）俞素芬^#,唐林娜,陈佳洁,张晓琛,蒋琦^*.不同量表对SHR-1210联合阿帕替尼治疗晚期非小细胞肺癌致手足综合征患者的生活质量评估效果比较[J].中华危重症医学杂志（电子版）,2020,13(4):284-287.

社会任职

浙江省抗癌协会癌痛专委会    青年委员